We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

15 hedge funds and large institutions have $1.94M invested in Acorda Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

281% more call options, than puts

Call options by funds: $347K | Put options by funds: $91K

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

48% less capital invested

Capital invested by funds: $3.71M → $1.94M (-$1.77M)

48% less funds holding

Funds holding: 29 → 15 (-14)

87% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 15

Holders
15
Holders Change
-14
Holders Change %
-48.28%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
4
Closed
15
Calls
$347K
Puts
$91K
Net Calls
+$256K
Net Calls Change
+$254K

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$15.4K
2
Morgan Stanley
Morgan Stanley
New York
+$9.47K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$5.94K
4
BlackRock
BlackRock
New York
+$36
5
Wells Fargo
Wells Fargo
California
+$24

Top Sellers

1
DKCM
Davidson Kempner Capital Management
New York
-$416K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$128K
3
Millennium Management
Millennium Management
New York
-$102K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$93.6K
5
TSS
Two Sigma Securities
New York
-$82.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
DKCM
1
Davidson Kempner Capital Management
New York
$717K -$416K -35,009 -39%
Renaissance Technologies
2
Renaissance Technologies
New York
$593K +$15.4K +1,296 +3%
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$442K -$12 -1 -0%
BlackRock
4
BlackRock
New York
$88.2K +$36 +3 +0%
Wells Fargo
5
Wells Fargo
California
$48.7K +$24 +2 +0.1%
Deutsche Bank
6
Deutsche Bank
Germany
$22.1K – – –
Morgan Stanley
7
Morgan Stanley
New York
$16.6K +$9.47K +797 +166%
Royal Bank of Canada
8
Royal Bank of Canada
Ontario, Canada
$7K +$5.94K +500 +3,125%
Russell Investments Group
9
Russell Investments Group
United Kingdom
$3.9K – – –
Group One Trading
10
Group One Trading
Illinois
$2.65K -$1.47K -124 -38%
TRCT
11
Tower Research Capital (TRC)
New York
$104 -$6.95K -585 -99%
First Manhattan
12
First Manhattan
New York
$39 – – –
JP Morgan Chase
13
JP Morgan Chase
New York
$13 – – –
Fidelity Investments
14
Fidelity Investments
Massachusetts
$13 +$12 +1 New
Osaic Holdings
15
Osaic Holdings
Arizona
$13 +$12 +1 New
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
– -$128K -10,942 Closed
Millennium Management
17
Millennium Management
New York
– -$102K -8,724 Closed
Vanguard Group
18
Vanguard Group
Pennsylvania
– -$93.6K -7,989 Closed
TSS
19
Two Sigma Securities
New York
– -$82.7K -7,058 Closed
BCM
20
Bridgeway Capital Management
Texas
– -$45K -3,835 Closed
Geode Capital Management
21
Geode Capital Management
Massachusetts
– -$39.1K -3,335 Closed
SC
22
Saltoro Capital
Texas
– -$23.9K -2,570 Closed
Northern Trust
23
Northern Trust
Illinois
– -$22.9K -1,956 Closed
State Street
24
State Street
Massachusetts
– -$18.5K -1,582 Closed
Two Sigma Investments
25
Two Sigma Investments
New York
– -$15.9K -1,354 Closed
1
2

ACOR Hedge Fund Activity: Q2 2023 in Review

15 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2023, worth a combined $1.94M — down 48% from $3.71M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of ACOR and 2 opened new positions — a net loss of 13 holders — while 4 trimmed existing stakes and 5 added.

The largest buyer was Renaissance Technologies, adding an estimated $15.4K. The largest seller was Davidson Kempner Capital Management, cutting an estimated $416K.

  • 15 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2023, down from 29 in Q1 2023.
  • Funds reported $1.94M of Acorda Therapeutics stock for Q2 2023, down 48% quarter-over-quarter.
  • 2 funds opened new Acorda Therapeutics positions in Q2 2023 and 15 closed out, a net change of -13 holders.
  • The largest Acorda Therapeutics buyer in Q2 2023 was Renaissance Technologies, an estimated $15.4K added.
  • The largest Acorda Therapeutics seller in Q2 2023 was Davidson Kempner Capital Management, an estimated $416K sold.

Based on aggregated 13F filings for Q2 2023.